Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2022

Open Access 01-12-2022 | Acute Myeloid Leukemia | Review

Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies

Authors: Antonella Padella, Andrea Ghelli Luserna Di Rorà, Giovanni Marconi, Martina Ghetti, Giovanni Martinelli, Giorgia Simonetti

Published in: Journal of Hematology & Oncology | Issue 1/2022

Login to get access

Abstract

The members of the Poly(ADP‐ribose) polymerase (PARP) superfamily are involved in several biological processes and, in particular, in the DNA damage response (DDR). The most studied members, PARP1, PARP2 and PARP3, act as sensors of DNA damages, in order to activate different intracellular repair pathways, including single-strand repair, homologous recombination, conventional and alternative non-homologous end joining. This review recapitulates the functional role of PARPs in the DDR pathways, also in relationship with the cell cycle phases, which drives our knowledge of the mechanisms of action of PARP inhibitors (PARPi), encompassing inhibition of single-strand breaks and base excision repair, PARP trapping and sensitization to antileukemia immune responses. Several studies have demonstrated a preclinical activity of the current available PARPi, olaparib, rucaparib, niraparib, veliparib and talazoparib, as single agent and/or in combination with cytotoxic, hypomethylating or targeted drugs in acute leukemia, thus encouraging the development of clinical trials. We here summarize the most recent preclinical and clinical findings and discuss the synthetic lethal interactions of PARPi in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Despite the low frequency of genomic alterations of PARP and other DDR-related genes in acute leukemia, selective vulnerabilities have been reported in several disease subgroups, along with a “BRCAness phenotype.” AML carrying the RUNX1-RUNX1T1 or PML-RARA fusion genes or mutations in signaling genes (FLT3-ITD in combination with TET2 or TET2 and DNMT3A deficiency), cohesin complex members (STAG2), TP53 and BCOR as co-occurring lesions, IDH1/2 and ALL cases expressing the TCF3-HLF chimera or TET1 was highly sensitive to PARPi in preclinical studies. These data, along with the warning coming from the observation of cases of therapy-related myeloid malignancies among patients receiving PARPi for solid tumors treatment, indicate that PARPi represents a promising strategy in a personalized medicine setting. The characterization of the clonal and subclonal genetic background and of the DDR functionality is crucial to select acute leukemia patients that will likely benefit of PARPi-based therapeutic regimens.
Literature
1.
Jubin T, Kadam A, Jariwala M, Bhatt S, Sutariya S, Gani AR, et al. The PARP family: insights into functional aspects of Poly(ADP-ribose) polymerase-1 in cell growth and survival. Cell Prolif. 2016;49(4):421–37.PubMedPubMedCentralCrossRef
2.
3.
Eustermann S, Wu WF, Langelier MF, Yang JC, Easton LE, Riccio AA, et al. Structural basis of detection and signaling of DNA single-strand breaks by human PARP-1. Mol Cell. 2015;60(5):742–54.PubMedPubMedCentralCrossRef
4.
Lilyestrom W, van der Woerd MJ, Clark N, Luger K. Structural and biophysical studies of human PARP-1 in complex with damaged DNA. J Mol Biol. 2010;395(5):983–94.PubMedCrossRef
5.
Pascal JM. The comings and goings of PARP-1 in response to DNA damage. DNA Repair (Amst). 2018;71:177–82.CrossRef
6.
7.
Lüscher B, Bütepage M, Eckei L, Krieg S, Verheugd P, Shilton BH. ADP-ribosylation, a multifaceted posttranslational modification involved in the control of cell physiology in health and disease. Chem Rev. 2018;118(3):1092–136.PubMedCrossRef
8.
Beck C, Robert I, Reina-San-Martin B, Schreiber V, Dantzer F. Poly(ADP-ribose) polymerases in double-strand break repair: focus on PARP1, PARP2 and PARP3. Exp Cell Res. 2014;329(1):18–25.PubMedCrossRef
9.
Boehler C, Gauthier LR, Mortusewicz O, Biard DS, Saliou JM, Bresson A, et al. Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression. Proc Natl Acad Sci USA. 2011;108(7):2783–8.PubMedPubMedCentralCrossRef
10.
Daugherty MD, Young JM, Kerns JA, Malik HS. Rapid evolution of PARP genes suggests a broad role for ADP-ribosylation in host-virus conflicts. PLoS Genet. 2014;10(5):e1004403.PubMedPubMedCentralCrossRef
11.
12.
Qiu W, Lam R, Voytyuk O, Romanov V, Gordon R, Gebremeskel S, et al. Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2. Acta Crystallogr D Biol Crystallogr. 2014;70(Pt 10):2740–53.PubMedPubMedCentralCrossRef
13.
Tuncel H, Tanaka S, Oka S, Nakai S, Fukutomi R, Okamoto M, et al. PARP6, a mono(ADP-ribosyl) transferase and a negative regulator of cell proliferation, is involved in colorectal cancer development. Int J Oncol. 2012;41(6):2079–86.PubMedCrossRef
14.
Gozgit JM, Vasbinder MM, Abo RP, Kunii K, Kuplast-Barr KG, Gui B, et al. PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity. Cancer Cell. 2021;39(9):1214-1226.e10.PubMedCrossRef
15.
Yang CS, Jividen K, Spencer A, Dworak N, Ni L, Oostdyk LT, et al. Ubiquitin modification by the E3 ligase/ADP-ribosyltransferase Dtx3L/Parp9. Mol Cell. 2017;66(4):503–516.e5.
16.
Yu M, Schreek S, Cerni C, Schamberger C, Lesniewicz K, Poreba E, et al. PARP-10, a novel Myc-interacting protein with poly(ADP-ribose) polymerase activity, inhibits transformation. Oncogene. 2005;24(12):1982–93.PubMedCrossRef
17.
Verheugd P, Forst AH, Milke L, Herzog N, Feijs KLH, Kremmer E, et al. Regulation of NF-κB signalling by the mono-ADP-ribosyltransferase ARTD10. Nat Commun. 2013;4:1683.PubMedCrossRef
18.
Leung AKL, Vyas S, Rood JE, Bhutkar A, Sharp PA, Chang P. Poly(ADP-ribose) regulates stress responses and microRNA activity in the cytoplasm. Mol Cell. 2011;42(4):489–99.PubMedPubMedCentralCrossRef
19.
Li L, Zhao H, Liu P, Li C, Quanquin N, Ji X, et al. PARP12 suppresses Zika virus infection through PARP-dependent degradation of NS1 and NS3 viral proteins. Sci Signal. 2018;11(535):eaas9332.
20.
Seo GJ, Kincaid RP, Phanaksri T, Burke JM, Pare JM, Cox JE, et al. Reciprocal inhibition between intracellular antiviral signaling and the RNAi machinery in mammalian cells. Cell Host Microbe. 2013;14(4):435–45.PubMedCrossRef
21.
Cho SH, Goenka S, Henttinen T, Gudapati P, Reinikainen A, Eischen CM, et al. PARP-14, a member of the B aggressive lymphoma family, transduces survival signals in primary B cells. Blood. 2009;113(11):2416–25.PubMedPubMedCentralCrossRef
22.
Schuller M, Riedel K, Gibbs-Seymour I, Uth K, Sieg C, Gehring AP, et al. Discovery of a selective allosteric inhibitor targeting macrodomain 2 of polyadenosine-diphosphate-ribose polymerase 14. ACS Chem Biol. 2017;12(11):2866–74.PubMedPubMedCentralCrossRef
23.
Jwa M, Chang P. PARP16 is a tail-anchored endoplasmic reticulum protein required for the PERK-and IRE1α-mediated unfolded protein response. Nat Cell Biol. 2012;14(11):1223–30.PubMedPubMedCentralCrossRef
24.
Di Paola S, Micaroni M, Di Tullio G, Buccione R, Di Girolamo M. PARP16/ARTD15 is a novel endoplasmic-reticulum-associated mono-ADP-ribosyltransferase that interacts with, and modifies karyopherin-ß1. PLoS ONE. 2012;7(6):e37352.PubMedPubMedCentralCrossRef
25.
26.
Yélamos J, Schreiber V, Dantzer F. Toward specific functions of poly(ADP-ribose) polymerase-2. Trends Mol Med. 2008;14(4):169–78.PubMedCrossRef
27.
Rulten SL, Fisher AEO, Robert I, Zuma MC, Rouleau M, Ju L, et al. PARP-3 and APLF function together to accelerate nonhomologous end-joining. Mol Cell. 2011;41(1):33–45.PubMedCrossRef
28.
29.
El-Khamisy SF, Masutani M, Suzuki H, Caldecott KW. A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res. 2003;31(19):5526–33.PubMedPubMedCentralCrossRef
30.
Ronson GE, Piberger AL, Higgs MR, Olsen AL, Stewart GS, McHugh PJ, et al. PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation. Nat Commun. 2018;9(1):746.PubMedPubMedCentralCrossRef
31.
Caldecott KW, Aoufouchi S, Johnson P, Shall S. XRCC1 polypeptide interacts with DNA polymerase β and possibly poly(ADP-ribose) polymerase, and DNA ligase III is a novel molecular “nick-sensor” in vitro. Nucleic Nucleic Acids Res. 1996;24(22):4387–94.PubMedCrossRef
32.
Lebedeva NA, Rechkunova NI, Endutkin AV, Lavrik OI. Apurinic/apyrimidinic endonuclease 1 and Tyrosyl-DNA phosphodiesterase 1 prevent suicidal covalent DNA-protein crosslink at apurinic/apyrimidinic site. Front Cell Dev Biol. 2021;8:617301.PubMedPubMedCentralCrossRef
33.
Abbotts R, Wilson DM. Coordination of DNA single strand break Repair. Free Radic Biol Med. 2017;107:228–44.PubMedCrossRef
34.
Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006;6(10):789–802.PubMedCrossRef
35.
Yang SW, Burgin AB, Huizenga BN, Robertson CA, Yao KC, Nash HA. A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topoisomerases. Proc Natl Acad Sci USA. 1996;93(21):11534–9.PubMedPubMedCentralCrossRef
36.
Das BB, Huang SN, Murai J, Rehman I, Amé JC, Sengupta S, et al. PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage. Nucleic Acids Res. 2014;42(7):4435–49.PubMedPubMedCentralCrossRef
37.
Chapman JR, Taylor MRG, Boulton SJ. Playing the end game: DNA double-strand break repair pathway choice. Mol Cell. 2012;47(4):497–510.PubMedCrossRef
38.
Caron MC, Sharma AK, O’Sullivan J, Myler LR, Ferreira MT, Rodrigue A, et al. Poly(ADP-ribose) polymerase-1 antagonizes DNA resection at double-strand breaks. Nat Commun. 2019;10(1):2954.PubMedPubMedCentralCrossRef
39.
Mao Z, Bozzella M, Seluanov A, Gorbunova V. Comparison of nonhomologous end joining and homologous recombination in human cells. DNA Repair (Amst). 2008;7(10):1765–71.CrossRef
40.
41.
Karanam K, Kafri R, Loewer A, Lahav G. Quantitative live cell imaging reveals a gradual shift between DNA repair mechanisms and a maximal use of HR in mid S phase. Mol Cell. 2012;47(2):320–9.PubMedPubMedCentralCrossRef
42.
Chang HHY, Pannunzio NR, Adachi N, Lieber MR. Non-homologous DNA end joining and alternative pathways to double-strand break repair HHS Public Access. Nat Rev Mol Cell Biol. 2017;18(8):495–506.PubMedPubMedCentralCrossRef
43.
Han Y, Jin F, Xie Y, Liu Y, Hu S, Liu XD, et al. DNA-PKcs PARylation regulates DNA-PK kinase activity in the DNA damage response. Mol Med Rep. 2019;20(4):3609–16.PubMedPubMedCentral
44.
45.
Davis AJ, Chen DJ. DNA double strand break repair via non-homologous end-joining. Transl Cancer Res. 2013;2(3):130–43.PubMed
46.
Yu W, Lescale C, Babin L, Bedora-Faure M, Lenden-Hasse H, Baron L, et al. Repair of G1 induced DNA double-strand breaks in S-G2/M by alternative NHEJ. Nat Commun. 2020;11(1):5239.PubMedPubMedCentralCrossRef
47.
Wyatt DW, Feng W, Conlin MP, Yousefzadeh MJ, Roberts SA, Mieczkowski P, et al. Essential roles for polymerase θ-mediated end joining in the repair of chromosome breaks. Mol Cell. 2016;63(4):662–73.PubMedPubMedCentralCrossRef
48.
Xiong X, Du Z, Wang Y, Feng Z, Fan P, Yan C, et al. 53BP1 promotes microhomology-mediated end-joining in G1-phase cells. Nucleic Acids Res. 2015;43(3):1659–70.PubMedPubMedCentralCrossRef
49.
50.
51.
Anand R, Ranjha L, Cannavo E, Cejka P. Phosphorylated CtIP functions as a co-factor of the MRE11-RAD50-NBS1 endonuclease in DNA end resection. Mol Cell. 2016;64(5):940–50.PubMedCrossRef
52.
Kent T, Chandramouly G, Mcdevitt SM, Ozdemir AY, Pomerantz RT. Mechanism of microhomology-mediated end-joining promoted by human DNA polymerase θ. Nat Struct Mol Biol. 2015;22(3):230–7.PubMedPubMedCentralCrossRef
53.
Okano S, Lan L, Tomkinson AE, Yasui A. Translocation of XRCC1 and DNA ligase IIIα from centrosomes to chromosomes in response to DNA damage in mitotic human cells. Nucleic Acids Res. 2005;33(1):422–9.PubMedPubMedCentralCrossRef
54.
Moynahan ME, Jasin M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol. 2010;11(3):196–207.PubMedPubMedCentralCrossRef
55.
Haince J-F, McDonald D, Rodrigue A, Déry U, Masson J-Y, Hendzel MJ, et al. PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites. J Biol Chem. 2008;283(2):1197–208.PubMedCrossRef
56.
Cruz-García A, López-Saavedra A, Huertas P. BRCA1 accelerates CtIP-ediated DNA-end resection. Cell Rep. 2014;9(2):451–9.PubMedCrossRef
57.
Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell. 1997;88(2):265–75.PubMedCrossRef
58.
59.
Wu J, Huen MSY, Lu L-Y, Ye L, Dou Y, Ljungman M, et al. Histone ubiquitination associates with BRCA1-dependent DNA damage response. Mol Cell Biol. 2009;29(3):849–60.PubMedCrossRef
60.
61.
Hu Y, Petit SA, Ficarro SB, Toomire KJ, Xie A, Lim E, et al. PARP1-driven Poly-ADP-ribosylation regulates BRCA1 function in homologous recombination mediated DNA repair. Cancer Discov. 2014;4(12):1430–47.PubMedPubMedCentralCrossRef
62.
Prakash R, Zhang Y, Feng W, Jasin M. Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb Perspect Biol. 2015;7(4):016600.CrossRef
63.
Li X, Heyer WD. Homologous recombination in DNA repair and DNA damage tolerance. Cell Res. 2008;18(1):99–113.PubMedCrossRef
64.
65.
Ellrott K, Bailey MH, Saksena G, Covington KR, Kandoth C, Stewart C, et al. Scalable open science approach for mutation calling of tumor exomes using multiple genomic pipelines. Cell Syst. 2018;6(3):271-281.e7.PubMedPubMedCentralCrossRef
66.
Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562(7728):526–31.PubMedPubMedCentralCrossRef
67.
Simonetti G, Padella A, do Valle IF, Fontana MC, Fonzi E, Bruno S, et al. Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery. Cancer. 2019;125(5):712–25.PubMedCrossRef
68.
Simonetti G, Mengucci C, Padella A, Fonzi E, Picone G, Delpino C, et al. Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations. Leukemia. 2021;35(10):2813–26.PubMedPubMedCentralCrossRef
69.
Bolouri H, Farrar JE, Triche T, Ries RE, Lim EL, Alonzo TA, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2019;25(3):530.PubMedPubMedCentralCrossRef
70.
Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang Y-L, Pei D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371(11):1005–15.PubMedPubMedCentralCrossRef
71.
Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, et al. Tumour lineage shapes BRCA-mediated phenotypes. Nature. 2019;571(7766):576–9.PubMedPubMedCentralCrossRef
72.
Zámborszky J, Szikriszt B, Gervai JZ, Pipek O, Póti Á, Krzystanek M, et al. Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions. Oncogene. 2017;36(6):746–55.PubMedCrossRef
73.
Seedhouse C, Faulkner R, Ashraf N, Das-Gupta E, Russell N. Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res. 2004;10(8):2675–80.PubMedCrossRef
74.
Jacoby MA, De RE, Pizarro J, Shao J, Koboldt DC, Fulton RS, et al. The DNA double-strand break response is abnormal in myeloblasts from patients with therapy-related acute myeloid leukemia. Leukemia. 2014;28(6):1242–51.PubMedCrossRef
75.
76.
Tischkowitz MD, Morgan NV, Grimwade D, Eddy C, Ball S, Vorechovsky I, et al. Deletion and reduced expression of the Fanconi anemia FANCA gene in sporadic acute myeloid leukemia. Leukemia. 2004;18(3):420–5.PubMedCrossRef
77.
Fontana MC, Marconi G, Feenstra JDM, Fonzi E, Papayannidis C, Ghelli Luserna Di Rorá A, et al. Chromothripsis in acute myeloid leukemia: biological features and impact on survival. Leukemia. 2018;32(7):1609–20.PubMedPubMedCentralCrossRef
78.
Rischewski JR, Clausen H, Leber V, Niemeyer C, Ritter J, Schindler D, et al. A heterozygous frameshift mutation in the Fanconi Anemia C gene in familiary T-aLL and secondary malignancy. Klin Padiatr. 2000;212(4):174–6.PubMedCrossRef
79.
80.
Padella A, Fontana MC, Marconi G, Fonzi E, Petracci E, Ferrari A, et al. Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway. Blood Cancer J. 2021;11(1):7.PubMedPubMedCentralCrossRef
81.
Grellety T, Peyraud F, Sevenet N, Tredan O, Dohollou N, Barouk-Simonet E, et al. Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA. Ann Oncol. 2020;31(6):822–3.PubMedCrossRef
82.
Kuemmel S, Harrach H, Schmutzler RK, Kostara A, Ziegler-Löhr K, Dyson MH, et al. Olaparib for metastatic breast cancer in a patient with a germline PALB2 variant. NPJ Breast Cancer. 2020;6:31.PubMedPubMedCentralCrossRef
83.
Mateo J, Porta N, Bianchini D, McGovern U, Elliott T, Jones R, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21(1):162–74.PubMedPubMedCentralCrossRef
84.
Tung NM, Robson ME, Ventz S, Santa-Maria CA, Nanda R, Marcom PK, et al. TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J Clin Oncol. 2020;38(36):4274–82.PubMedCrossRef
85.
Zheng F, Zhang Y, Chen S, Weng X, Rao Y, Fang H. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer. Biomed Pharmacother. 2020;123:109661.PubMedCrossRef
86.
Murai J, Huang SYN, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72(21):5588–99.PubMedPubMedCentralCrossRef
87.
Hanzlikova H, Kalasova I, Demin AA, Pennicott LE, Cihlarova Z, Caldecott KW. The importance of poly(ADP-ribose) polymerase as a sensor of unligated Okazaki fragments during DNA replication. Mol Cell. 2018;71(2):319-331.e3.PubMedPubMedCentralCrossRef
88.
89.
Parkes EE, Walker SM, Taggart LE, McCabe N, Knight LA, Wilkinson R, et al. Activation of STING-dependent innate immune signaling by S-phase-specific DNA damage in breast cancer. J Natl Cancer Inst. 2016;109(1):djw199.
90.
Pommier Y, O’Connor MJ, De Bono J. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci Transl Med. 2016 26;8(362):362ps17.
91.
92.
Sun W, Zhang Q, Wang R, Li Y, Sun Y, Yang L. Targeting DNA damage repair for immune checkpoint inhibition: mechanisms and potential clinical applications. Front Oncol. 2021;11:648687.PubMedPubMedCentralCrossRef
93.
Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, et al. Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas. Cell Rep. 2018;23(1):239–254.e6.
94.
95.
Chen Q, Sun L, Chen ZJ. Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat Immunol. 2016;17(10):1142–9.PubMedCrossRef
96.
Pantelidou C, Sonzogni O, Taveira MDO, Mehta AK, Kothari A, Wang D, et al. Parp inhibitor efficacy depends on CD8+ T-cell recruitment via intratumoral sting pathway activation in brca-deficient models of triple-negative breast cancer. Cancer Discov. 2019;9(6):722–37.PubMedPubMedCentralCrossRef
97.
Jiao S, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res. 2017;23(14):3711–20.PubMedPubMedCentralCrossRef
98.
Mosely SIS, Prime JE, Sainson RCA, Koopmann JO, Wang DYQ, Greenawalt DM, et al. Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery. Cancer Immunol Res. 2017;5(1):29–41.PubMedCrossRef
99.
Aurelius J, Thorén FB, Akhiani AA, Brune M, Palmqvist L, Hansson M, et al. Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91phox expression and the PARP-1/PAR pathway of apoptosis. Blood. 2012;119(24):5832–7.PubMedPubMedCentralCrossRef
100.
Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 2005;436(7054):1186–90.PubMedPubMedCentralCrossRef
101.
Paczulla AM, Rothfelder K, Raffel S, Konantz M, Steinbacher J, Wang H, et al. Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature. 2019;572(7768):254–9.PubMedPubMedCentralCrossRef
102.
Meng XW, Koh BD, Zhang JS, Flatten KS, Schneider PA, Billadeau DD, et al. Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression. J Biol Chem. 2014;289(30):20543–58.PubMedPubMedCentralCrossRef
103.
Casorelli I, Tenedini E, Tagliafico E, Blasi MF, Giuliani A, Crescenzi M, et al. Identification of a molecular signature for leukemic promyelocytes and their normal counterparts: Focus on DNA repair genes. Leukemia. 2006;20(11):1978–88.PubMedCrossRef
104.
Faraoni I, Aloisio F, De Gabrieli A, Consalvo MI, Lavorgna S, Voso MT, et al. The poly(ADP-ribose) polymerase inhibitor olaparib induces up-regulation of death receptors in primary acute myeloid leukemia blasts by NF-κB activation. Cancer Lett. 2018;423:127–38.PubMedCrossRef
105.
Li D, Luo Y, Chen X, Zhang LY, Wang T, Zhuang Y, et al. NF-kB and Poly(ADP-ribose) polymerase 1 form a positive feedback loop that regulates DNA repair in acute myeloid leukemia cells. Mol Cancer Res. 2019;17(3):761–72.PubMedCrossRef
106.
Orta ML, Höglund A, Calderón-Montaño JM, Domínguez I, Burgos-Morón E, Visnes T, et al. The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2′-deoxycytidine lesions. Nucleic Acids Res. 2014;42(14):9108–20.PubMedPubMedCentralCrossRef
107.
Garcia TB, Snedeker JC, Baturin D, Gardner L, Fosmire SP, Zhou C, et al. A small-molecule inhibitor of WEE1, AZD1775, synergizes with olaparib by impairing homologous recombination and enhancing DNA damage and apoptosis in acute leukemia. Mol Cancer Ther. 2017;16(10):2058–68.PubMedPubMedCentralCrossRef
108.
Shen Y, Aoyagi-Scharber M, Wang B. Trapping poly(ADP-ribose) polymerase. J Pharmacol Exp Ther. 2015;353(3):446–57.PubMedCrossRef
109.
Antolin AA, Ameratunga M, Banerji U, Clarke PA, Workman P, Al-Lazikani B. The kinase polypharmacology landscape of clinical PARP inhibitors. Sci Rep. 2020;10(1):2585.PubMedPubMedCentralCrossRef
110.
Falzacappa MV, Ronchini C, Faretta M, Iacobucci I, Di Rorà AG, Martinelli G, et al. The Combination of the PARP inhibitor rucaparib and 5FU is an effective strategy for treating acute leukemias. Mol Cancer Ther. 2015;14(4):889–98.PubMedCrossRef
111.
Giansanti M, De Gabrieli A, Prete SP, Ottone T, Divona MD, Karimi T, et al. Poly(ADP-ribose) polymerase inhibitors for arsenic trioxide-resistant acute promyelocytic leukemia: synergistic in vitro antitumor effects with hypomethylating agents or high-dose vitamin C. J Pharmacol Exp Ther. 2021;377(3):385–97.PubMedCrossRef
112.
Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Champlin RE, et al. Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells. Oncotarget. 2017;9(3):3908–21.PubMedPubMedCentralCrossRef
113.
Horton TM, Jenkins G, Pati D, Zhang L, Dolan ME, Ribes-Zamora A, et al. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: Influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther. 2009;8(8):2232–42.PubMedPubMedCentralCrossRef
114.
Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007;13(9):2728–37.PubMedCrossRef
115.
Kummar S, Kinders R, Gutierrez M, Rubinstein L, Parchment RE, Phillips LR, et al. Inhibition of Poly(ADP-ribose) polymerase (PARP) by ABT-888 in patients with advanced malignancies: Results of a phase 0 trial. J Clin Oncol. 2009;27(16):2705–11.PubMedPubMedCentralCrossRef
116.
Muvarak NE, Chowdhury K, Xia L, Robert C, Choi EY, Cai Y, et al. Enhancing the cytotoxic effects of PARP inhibitors with DNA demethylating agents—a potential therapy for cancer. Cancer Cell. 2016;30(4):637–50.PubMedPubMedCentralCrossRef
117.
Kohl V, Flach J, Naumann N, Brendel S, Kleiner H, Weiss C, et al. Antileukemic efficacy in vitro of talazoparib and APE1 inhibitor III combined with decitabine in myeloid malignancies. Cancers (Basel). 2019;11(10):1493.CrossRef
118.
Kogan AA, Mclaughlin LJ, Topper M, Muvarak N, Stojanovic L, Creed TM, et al. DNA demethylating agents generate a brcaness effect in multiple sporadic tumor types: prediction for sensitivity to PARP inhibitors in AML. Blood. 2017;130(Suppl 1):3347.
119.
Farmer H, McCabe H, Lord CJ, Tutt AHJ, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–21.CrossRefPubMed
120.
Li X, Li C, Jin J, Wang J, Huang J, Ma Z, et al. High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects. EBioMedicine. 2018;38:47–56.PubMedPubMedCentralCrossRef
121.
Robert C, Nagaria PK, Pawar N, Adewuyi A, Gojo I, Meyers DJ, et al. Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin. Leuk Res. 2016;45:14–23.PubMedPubMedCentralCrossRef
122.
123.
Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913–7.PubMedCrossRef
124.
Scardocci A, Guidi F, D’Alo F, Gumiero D, Fabiani E, Diruscio A, et al. Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia. Br J Cancer. 2006;95(8):1108–13.PubMedPubMedCentralCrossRef
125.
Faraoni I, Compagnone M, Lavorgna S, Angelini DF, Cencioni MT, Piras E, et al. BRCA1, PARP1 and γH2AX in acute myeloid leukemia: role as biomarkers of response to the PARP inhibitor olaparib. Biochim Biophys Acta Mol Basis Dis. 2015;1852(3):462–72.CrossRef
126.
Zimmermann M, Murina O, Reijns MAM, Agathanggelou A, Challis R, Tarnauskaite Ž, et al. CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions. Nature. 2018;559(7713):285–9.PubMedPubMedCentralCrossRef
127.
Chen SH, Yu X. Targeting dePARylation selectively suppresses DNA repair-defective and PARP inhibitor-resistant malignancies. Sci Adv. 2019;5(4):eaav4340.
128.
Giovannini S, Weller MC, Repmann S, Moch H, Jiricny J. Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage. Nucleic Acids Res. 2019;47(17):9132–43.PubMedPubMedCentralCrossRef
129.
Pillay N, Tighe A, Nelson L, Littler S, Coulson-Gilmer C, Bah N, et al. DNA replication vulnerabilities render ovarian cancer cells sensitive to poly(ADP-ribose) glycohydrolase inhibitors. Cancer Cell. 2019;35(3):519-533.e8.PubMedPubMedCentralCrossRef
130.
Turner N, Tutt A, Ashworth A. Hallmarks of “BRCAness” in sporadic cancers. Nat Rev Cancer. 2004;4(10):814–9.PubMedCrossRef
131.
Esposito MT, Zhao L, Fung TK, Rane JK, Wilson A, Martin N, et al. Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors. Nat Med. 2015;21(12):1481–90.PubMedCrossRef
132.
Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Hoser G, Maifrede S, et al. Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells. J Clin Invest. 2017;127(6):2392–406.PubMedPubMedCentralCrossRef
133.
Maifrede S, Martinez E, Nieborowska-Skorska M, Di Marcantonio D, Hulse M, Le BV, et al. MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs. Blood Adv. 2017;1(19):1467–72.PubMedPubMedCentralCrossRef
134.
Piao J, Takai S, Kamiya T, Inukai T, Sugita K, Ohyashiki K, et al. Poly(ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF–positive leukemic cells. Cancer Lett. 2017;386:131–40.PubMedCrossRef
135.
Maifrede S, Le BV, Nieborowska-Skorska M, Golovine K, Sullivan-Reed K, Dunuwille WM, et al. TET2 and DNMT3A mutations exert divergent effects on DNA repair and sensitivity of leukemia cells to PARP inhibitors. Cancer Res. 2021;81(19):5089–101.PubMedCrossRefPubMedCentral
136.
Maifrede S, Nieborowska-Skorska M, Sullivan-Reed K, Dasgupta Y, Podszywalow-Bartnicka P, Le BV, et al. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors. Blood. 2018;132(1):67–77.PubMedPubMedCentralCrossRef
137.
Le BV, Podszywalow-Bartnicka P, Maifrede S, Sullivan-Reed K, Nieborowska-Skorska M, Golovine K, et al. TGFβR-SMAD3 signaling induces resistance to PARP inhibitors in the bone marrow microenvironment. Cell Rep. 2020;33(1):108221.PubMedPubMedCentralCrossRef
138.
Nieborowska-Skorska M, Paietta EM, Levine RL, Fernandez HF, Tallman MS, Litzow MR, et al. Inhibition of the mutated c-KIT kinase in AML1-ETO–positive leukemia cells restores sensitivity to PARP inhibitor. Blood Adv. 2019;3(23):4050–4.PubMedPubMedCentralCrossRef
139.
Patel PR, Senyuk V, Rodriguez NS, Oh AL, Bonetti E, Mahmud D, et al. Synergistic cytotoxic effect of busulfan and the PARP inhibitor veliparib in myeloproliferative neoplasms. Biol Blood Marrow Transplant. 2019;25(5):855–60.PubMedCrossRef
140.
Tothova Z, Valton AL, Gorelov RA, Vallurupalli M, Krill-Burger JM, Holmes A, et al. Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML. JCI Insight. 2021;6(3):e142149.PubMedCentralCrossRef
141.
Iacobucci I, Qu C, Varotto E, Janke LJ, Yang X, Seth A, et al. Modeling and targeting of erythroleukemia by hematopoietic genome editing. Blood. 2021;137(12):1628–40.PubMedCrossRefPubMedCentral
142.
Molenaar RJ, Radivoyevitch T, Nagata Y, Khurshed M, Przychodzen B, Makishima H, et al. Idh1/2 mutations sensitize acute myeloid leukemia to parp inhibition and this is reversed by idh1/2-mutant inhibitors. Clin Cancer Res. 2018;24(7):1705–15.PubMedPubMedCentralCrossRef
143.
Sulkowski PL, Corso CD, Robinson ND, Scanlon SE, Purshouse KR, Bai H, et al. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Sci Transl Med. 2017;9(375):eaal2463.
144.
Bamezai S, Demir D, Pulikkottil AJ, Ciccarone F, Fischbein E, Sinha A, et al. TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition. Leukemia. 2021;35(2):389–403.PubMedCrossRef
145.
Padella A, Simonetti G, Paciello G, Giotopoulos G, Baldazzi C, Righi S, et al. Novel and rare fusion transcripts involving transcription factors and tumor suppressor genes in acute myeloid leukemia. Cancers (Basel). 2019;11(12):1951.CrossRef
146.
Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson G, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059–74.PubMedCrossRef
147.
Krejci O, Wunderlich M, Geiger H, Chou F-S, Schleimer D, Jansen M, et al. p53 signaling in response to increased DNA damage sensitizes AML1-ETO cells to stress-induced death. Blood. 2008;111(4):2190–9.PubMedPubMedCentralCrossRef
148.
Forster VJ, Nahari MH, Martinez-Soria N, Bradburn AK, Ptasinska A, Assi SA, et al. The leukemia-associated RUNX1/ETO oncoprotein confers a mutator phenotype. Leukemia. 2015;30(1):250–3.PubMed
149.
Santos MA, Faryabi RB, Ergen AV, Day AM, Malhowski A, Canela A, et al. DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier. Nature. 2014;514(7520):107–11.PubMedPubMedCentralCrossRef
150.
Bagrintseva K, Geisenhof S, Kern R, Eichenlaub S, Reindl C, Ellwart JW, et al. FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L). Blood. 2005;105(9):3679–85.PubMedCrossRef
151.
Seedhouse CH, Hunter HM, Lloyd-Lewis B, Massip AM, Pallis M, Carter GI, et al. DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412. Leukemia. 2006;20(12):2130–6.PubMedCrossRef
152.
Gaymes TJ, Mohamedali A, Eiliazadeh AL, Darling D, Mufti GJ. FLT3 and JAK2 mutations in acute myeloid leukemia promote interchromosomal homologous recombination and the potential for copy neutral loss of heterozygosity. Cancer Res. 2017;77(7):1697–708.PubMedCrossRef
153.
Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell. 2007;128(1):157–70.PubMedCrossRef
154.
Thota S, Viny AD, Makishima H, Spitzer B, Radivoyevitch T, Przychodzen B, et al. Genetic alterations of the cohesin complex genes in myeloid malignancies. Blood. 2014;124(11):1790–8.PubMedPubMedCentralCrossRef
155.
Mondal G, Stevers M, Goode B, Ashworth A, Solomon DA. A requirement for STAG2 in replication fork progression creates a targetable synthetic lethality in cohesin-mutant cancers. Nat Commun. 2019;10(1):1686.PubMedPubMedCentralCrossRef
156.
Inoue S, Li WY, Tseng A, Beerman I, Elia AJ, Bendall SC, et al. Mutant IDH1 downregulates ATM and alters DNA repair and sensitivity to DNA damage independent of TET2. Cancer Cell. 2016;30(2):337–48.PubMedPubMedCentralCrossRef
157.
Ciccarone F, Valentini E, Zampieri M, Caiafa P. 5mC-hydroxylase activity is influenced by the PARylation of TET1 enzyme. Oncotarget. 2015;6(27):24333–47.PubMedPubMedCentralCrossRef
158.
Roper SJ, Chrysanthou S, Senner CE, Sienerth A, Gnan S, Murray A, et al. ADP-ribosyltransferases Parp1 and Parp7 safeguard pluripotency of ES cells. Nucleic Acids Res. 2014;42(14):8914–27.PubMedPubMedCentralCrossRef
159.
Klisovic RB, Tricot G, Coutre S, Kovacsovics T, Giles F, Genna T, et al. A phase I trial of AVN944 in patients with advanced hematologic malignancies. J Clin Oncol. 2007;25:14026–14026.CrossRef
160.
Gojo I, Beumer JH, Pratz KW, McDevitt MA, Baer MR, Blackford AL, et al. A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia. Clin Cancer Res. 2017;23(3):697–706.PubMedCrossRef
161.
Pratz KW, Rudek MA, Gojo I, Litzow MR, McDevitt MA, Ji J, et al. A phase I study of topotecan, carboplatin and the PARP inhibitor veliparib in acute leukemias, aggressive myeloproliferative neoplasms, and chronic myelomonocytic leukemia. Clin Cancer Res. 2017;23(4):899–907.PubMedCrossRef
162.
De Botton S, Sabri S, Daugas E, Zermati Y, Guidotti JE, Hermine O, et al. Platelet formation is the consequence of caspase activation within megakaryocytes. Blood. 2002;100(4):1310–7.PubMedCrossRef
163.
Mirza MR, Benigno B, Dørum A, Mahner S, Bessette P, Barceló IB, et al. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial. Gynecol Oncol. 2020;159(2):442–8.PubMedCrossRef
164.
Yarchoan M, Myzak MC, Johnson BA, De Jesus-Acosta AD, Le DT, Jaffee EM, et al. Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. Oncotarget. 2017;8(27):44073–81.PubMedPubMedCentralCrossRef
165.
Skelding KA, Lincz LF. PARP inhibitors and haematological malignancies—friend or foe? Cancers (Basel). 2021;13(21):5328.CrossRef
166.
Morton LM, Dores GM, Schonfeld SJ, Linet MS, Sigel BS, Lam CJK, et al. Association of chemotherapy for solid tumors with development of therapy-related myelodysplastic syndrome or acute myeloid leukemia in the modern era. JAMA Oncol. 2019;5(3):318–25.PubMedCrossRef
167.
Bhatia S. Therapy-related myelodysplasia and acute myeloid leukemia. Semin Oncol. 2013;40:666–75.PubMedCrossRef
168.
Ball S, Sultan A, Zaw MH, Thein KZ. Secondary hematologic malignancies with poly adenosine diphosphate ribose polymerase inhibitors: Is the buzz real? Insights from a meta-analysis of phase 3 randomized controlled trials. J Geriatr Oncol. 2019;10(3):518–20.PubMedCrossRef
169.
Morice PM, Leary A, Dolladille C, Chrétien B, Poulain L, González-Martín A, et al. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. Lancet Haematol. 2021;8(2):e122–34.PubMedCrossRef
170.
Iluta S, Pasca S, Gafencu G, Jurj A, Terec A, Teodorescu P, et al. Azacytidine plus olaparib for relapsed acute myeloid leukaemia, ineligible for intensive chemotherapy, diagnosed with a synchronous malignancy. J Cell Mol Med. 2021;25(13):6094–102.PubMedCentralCrossRef
171.
Bolton KL, Ptashkin RN, Gao T, Braunstein L, Devlin SM, Kelly D, et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet. 2020;52(11):1219–26.PubMedPubMedCentralCrossRef
172.
Mufti G, Estey E, Popat R, Mattison R, Menne T, Azar J, et al. Results of a phase 1 study of BMN 673, a potent and specific PARP-1/2 inhibitor, in patients with advanced hematological malignancies. Haematologica. 2014;99:33–4.CrossRef
Metadata
Title
Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies
Authors
Antonella Padella
Andrea Ghelli Luserna Di Rorà
Giovanni Marconi
Martina Ghetti
Giovanni Martinelli
Giorgia Simonetti
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2022
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-022-01228-0

Other articles of this Issue 1/2022

Journal of Hematology & Oncology 1/2022 Go to the issue

Review

Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination

Review

Single-cell sequencing: a promising approach for uncovering the mechanisms of tumor metastasis

Correspondence

Double knockout CRISPR screen for cancer resistance to T cell cytotoxicity

Review

Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021

Review

Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets

Research

Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits